Track record · closed signal

Novo Nordisk A/S (NVO) — closed signal from June 3, 2026

Target reached Published before the outcome was known, scored automatically when the window closed on September 1, 2026 — +7.3% at the close.

Predicted vs. what happened

NVO price · publication thesis → realized outcomesplit-adjusted

$39.97 – $42.41Entry zone — fair-value band

$42.06Published — price the day we called it

$45.69Target — the price the thesis aimed for

$51.46Peak — highest point inside the window, not a realized return

$45.12Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 20 days.

At window close

+7.3%

realized, from the publication price to the last close inside the window

Peak gain

+22.3%

peak, from the publication price — not a realized return

S&P 500, same window

+1.3%

SPY over the identical days, dividend-adjusted

Window close

$45.12

last close inside the window, ended September 1, 2026

Peak price

$51.46

peak on July 29, 2026 — not a realized return

Days to target

The thesis — published June 3, 2026

Predicted growth

+10%

over the measurement window

Target price

$45.69

the price the thesis aimed for

Entry zone

$39.97 – $42.41

the fair-value band we waited for

Price at publication

$42.06

published June 3, 2026

Confidence

74%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Novo Nordisk gives steady healthcare exposure to the growing GLP-1 obesity market at a more reasonable price than many rivals. The new oral Wegovy release outside the U.S. is a clear commercial boost. A recent earnings shortfall, debt levels, and weak market momentum limit short-term upside, so the rebound case is measured, not aggressive.

Primary drivers

New oral Wegovy expands where the drug can be sold
Strong, lasting demand for obesity treatments
Lower price versus peers supports a modest rebound
Recent oversold drop gives clearer risk and reward levels

How it played out

NVO: target reached in 20 days

Lyra published a measured rebound thesis from $42.06, with 10% expected growth and a $45.69 target. The thesis pointed to the oral Wegovy rollout outside the U.S., lasting demand for obesity treatments, a lower price than peers, and an oversold drop. It also noted an earnings shortfall, debt, and weak momentum.

The shares reached the target in 20 days. They later peaked at $51.46 on July 29, a 22.3% gain, before ending the window at $45.12. The thesis played out and exceeded its expected growth, although the closing price was below the target.

What happened during the window

On July 15, Novo Nordisk announced European Commission approval of the Wegovy pill for weight management. On August 4, the company reported Q2 2026 adjusted operating profit of DKK 33,389 million and raised its full-year outlook.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All NVO signals